A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity

What Was Tested

In this phase 4 trial, researchers set out to test Semaglutide for fat loss, obesity & body recomposition.

It had two arms (groups): one (experimental) and one (active comparator).

The registry classes the interventions as drug.

Who Took Part

The registry lists 72 planned participants were the target.

It was open to people of any sex aged from 18 years up to 64 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Men and women, aged 18 to 64 years inclusive at the time of signing the informed consent form.

The full record lists 4 inclusion and 20 exclusion criteria; among the exclusions: history or planned bariatric surgery or use of a weight-loss device during the trial; obesity induced by other endocrinologic disorders or monogenic mutations, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroidism, cushing's syndrome, insulinoma, acromegaly, or hypogonadism; end-stage renal disease, or requiring long-term/intermittent hemodialysis or peritoneal dialysis.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

The Semaglutide group and the comparison group ran side by side rather than switching.

Being open-label, the Semaglutide study did not mask who received what.

It started in 2026-09-01 with completion listed for 2027-12-30.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percentage change in body weight from baseline to week 24 (time frame: Baseline (Week 0) to Week 24).

It also tracked 3 secondary outcomes, for example Absolute change in body weight from baseline to week 24 (kg), Mean change in waist circumference from baseline to week 24 (cm) and Mean change in body mass index (BMI) from baseline to week 24 (kg/m²).

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 72 people with fat loss, obesity & body recomposition.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, Fat loss, obesity & body recomposition research.